Project Grant R00CA263149
Award Date
7/2/24
Completion Date
6/30/27
Dollars Obligated
$249K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $201,172 to Duke University from August 1, 2024 to July 31, 2026 to conduct research on using cell-free DNA methylation patterns as a biomarker for tumor biology and clinical outcomes in glioblastoma patients. The key products or services to be delivered under this grant include: Developing a non-invasive method to longitudinally profile glioblastoma tumors using...
This federal Project Grant award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) provides $475,431 to The Trustees of the University of Pennsylvania to decipher mechanisms of transcriptional repression that drive diffuse midline glioma (DMG), a deadly form of brain cancer. The key objectives are to: 1) Define the critical Polycomb Repressive Complex 1 (PRC1) configuration that mediates inappropriate transcriptional...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) totaling $227,906 will support the development of a novel technology for spatially resolved multi-omics sequencing of formalin-fixed paraffin-embedded (FFPE) tissue samples at the cellular level. The key products and services to be delivered under this award include: Developing spatial epigenome sequencing capabilities to measure gene expression and epigenetic characteristics directly in...
The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived tumor...
This Project Grant award from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) provides $682,596 to The University of Texas Southwestern Medical Center to investigate the metabolic mechanisms underlying glioma progression. The project aims to: Dissect the molecular basis for metabolic reprogramming and aberrant metabolite secretion in high-grade gliomas, Determine the impact of this aberrant metabolite secretion on the excitability of the tumor...
This $638,804 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Pennsylvania State University's Milton S. Hershey Medical Center aims to integrate cerebrospinal fluid (CSF) proteogenomic analyses to improve diagnosis and management of diffuse gliomas, the most common primary malignant adult brain tumors. The key objectives are to: 1) validate preliminary findings on CSF-based proteomic signatures that can differentiate diffuse...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,200,000 to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The project aims to target the extracellular glucose-regulated protein 78 (eGRP78), which is upregulated in drug-resistant recurrent brain cancers and promotes tumor growth, immune evasion, and stem cell formation. The...
The National Cancer Institute (NCI) awarded a $954,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to investigate how aging promotes the growth of glioblastoma, one of the most lethal forms of cancer. The research aims to leverage insights from the biology of neural stem cells and the molecular circuitry of cancer stem cells to understand how aging creates a tumor microenvironment that supports the survival and proliferation of glioblastoma. The...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Chicago to develop and apply a novel epigenome sequencing platform called "Glycosylase-Implemented Epigenome Sequencing" (GLIMP-SEQ). The $230,010 award, running from February 1, 2025 to January 31, 2028, aims to enable highly sensitive and accurate profiling of 5-methylcytosine (5mC) in degraded clinical samples such as formalin-fixed,...